Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Maximal Use Systemic Exposure (MUSE) Study Evaluating the Safety and Efficacy of LEO 90100 Used Once Daily in Subjects With Extensive Psoriasis Vulgaris

Next Previous
Trial Profile

A Phase 2 Maximal Use Systemic Exposure (MUSE) Study Evaluating the Safety and Efficacy of LEO 90100 Used Once Daily in Subjects With Extensive Psoriasis Vulgaris

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Betamethasone-dipropionate/calcipotriol (Primary)
  • Indications Plaque psoriasis
  • Focus Pharmacodynamics
  • Acronyms MUSE

    • Most Recent Events

    • 12 Jul 2016 According to a Leo Pharma media release, following the results from from this MUSE study and a phase III PSO-FAST trial (Profile 233523) the company has launched Enstilar foam spray for psoriasis in the United Kingdom.
    • 26 Apr 2016 According to Leo Pharma media release, based on the results from this MUSE study and other PSO-FAST trial (see CTP 700233523), the company received marketing authorisation for Enstilar (calcipotriol/betamethasone dipropionate) for the topical treatment of plaque psoriasis in patients 18 years of age or older, in the United Kingdom.
    • 21 Mar 2016 According to a LEO Pharma media release, calcipotriol/betamethasone dipropionate (Enstilar) was approved for the treatment of plaque psoriasis by the US FDA in October 2015, and it received marketing approval in the EU in March 2016.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top